Difference between revisions of "Sunitinib"

Jump to navigation Jump to search
10 bytes added ,  19:57, 8 November 2018
no edit summary
 
Line 1: Line 1:
'''Sunitinib''' (marketed with the brand name ''Sutent'') is a [[tyrosine kinase inhibitor]] used to treat [[renal cell carcinoma]] (RCC).
'''Sunitinib''' (marketed with the brand name ''Sutent'' by Pfizer) is a [[tyrosine kinase inhibitor]] used to treat [[renal cell carcinoma]] (RCC).


In RCC acts on:<ref>{{Cite journal  | last1 = Toon | first1 = CW. | last2 = Hasovits | first2 = C. | last3 = Paik | first3 = J. | last4 = Field | first4 = M. | last5 = Chou | first5 = A. | last6 = Hugh | first6 = TJ. | last7 = Pavlakis | first7 = N. | last8 = Gill | first8 = AJ. | title = Skin rash, a kidney mass and a family mystery dating back to World War II. | journal = Med J Aust | volume = 201 | issue = 1 | pages = 58-60 | month = Jul | year = 2014 | doi =  | PMID = 24999901 }}</ref>
In RCC acts on:<ref>{{Cite journal  | last1 = Toon | first1 = CW. | last2 = Hasovits | first2 = C. | last3 = Paik | first3 = J. | last4 = Field | first4 = M. | last5 = Chou | first5 = A. | last6 = Hugh | first6 = TJ. | last7 = Pavlakis | first7 = N. | last8 = Gill | first8 = AJ. | title = Skin rash, a kidney mass and a family mystery dating back to World War II. | journal = Med J Aust | volume = 201 | issue = 1 | pages = 58-60 | month = Jul | year = 2014 | doi =  | PMID = 24999901 }}</ref>
48,830

edits

Navigation menu